# UMN Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/umn-pharma

- Industry: Biotechnology
- Headquarters: Akita-shi, Japan
- Website: www.umnpharma.com
- Total disclosed funding: $29M
- Latest round: Series C (Feb 21, 2007)
- Investors on record: 22

## About

UMN Pharma, based in Japan, specializes in the development and production of biotechnology products, focusing on innovative vaccine solutions to combat infectious diseases.Founded in 2004 and headquartered in Akita-shi, Japan, UMN Pharma develops biotechnology products, particularly vaccines. The company went public in December 2012 by listing its common stocks on the Tokyo Stock Exchange Mothers market, with a valuation set between 1300 and 1600 JPY. The founder's history and prior ventures are not specified. To date, UMN Pharma has completed 8 deals, with its latest funding round being an IPO that raised JPY 4446.000 mn, matching the total amount raised.UMN Pharma, Inc. specializes in the development and production of cutting-edge biotechnological products, specifically focusing on innovative vaccine solutions. Their core offerings include a portfolio of vaccines designed to address various infectious diseases, leveraging advanced biotechnology to create gentler yet effective immunization options for patients. These vaccines are engineered to enhance efficacy while minimizing adverse effects, thereby catering to healthcare institutions and public health organizations. UMN Pharma's products are primarily marketed in Asia, particularly in Japan and emerging markets, aiming to serve both public and private healthcare sectors needing robust vaccination options to combat prevalent health threats.In the most recent fiscal year of 2018, UMN Pharma reported revenues of JPY 932,490 mn, with an EBITDA loss of JPY 5,460,930.UMN Pharma aims to expand its product offerings with new vaccines targeting additional infectious diseases, although specific release dates have not been disclosed. The company is also focused on expanding into new markets beyond Asia, targeting regions where vaccine demand is increasing. Recent funding from the IPO will be utilized to support these initiatives, which include strategic investments in research and development as well as market entry strategies. The successful public listing on December 11, 2012, facilitated this growth strategy, with financial advisors including Nomura and Mizuho.

## Funding rounds

- Series C, Feb 21, 2007, $19M — Dai-ichi Life Insurance, Ant Capital Partners, Nippon Venture Capital, AG Capital, JAFCO Group, ORIX, Tokyo Small and Medium Business Investment & Consultation, Yasuda Enterprise Development, Cybird Co., Ltd., Mitsubishi UFJ Capital, SPARX Group, Pacific Rim Ventures, Mizuho Capital, NIF SMBC Ventures, Nagoya Small and Medium Business Investment & Consultation, Collabo SANGAKUKAN, Rakuten Capital, Nomura Research and Advisory
- Series B, Feb 3, 2006, $7.5M — Japan Asia Investment Company, Resona Holdings, Mizuho Securities, ORIX, Tokyo Small and Medium Business Investment & Consultation, SPARX Group, Pacific Rim Ventures, Mizuho Capital, NIF SMBC Ventures, Nagoya Small and Medium Business Investment & Consultation, Nomura Research and Advisory
- Series B, Oct 17, 2005, $1.1M — Pacific Rim Ventures, NIF SMBC Ventures, Nomura Research and Advisory
- Series A, Jul 22, 2005, $0.9M — ASTEC, Pacific Rim Ventures
- Series A, Dec 31, 2004, $0.9M — ASTEC, Pacific Rim Ventures

## Investors

- ASTEC (https://capitalatlas.ai/funds/astec) — Series A
- Pacific Rim Ventures (https://capitalatlas.ai/funds/pacific-rim-ventures) — Series A, Series B, Series C
- NIF SMBC Ventures (https://capitalatlas.ai/funds/nif-smbc-ventures) — Series B, Series C
- Nomura Research and Advisory (https://capitalatlas.ai/funds/nomura-research-and-advisory) — Series B, Series C
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series B
- Resona Holdings — Series B
- Mizuho Securities — Series B
- ORIX (https://capitalatlas.ai/funds/orix) — Series B, Series C
- Tokyo Small and Medium Business Investment & Consultation (https://capitalatlas.ai/funds/tokyo-small-and-medium-business-investment-consultation) — Series B, Series C
- SPARX Group (https://capitalatlas.ai/funds/sparx-group) — Series B, Series C
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series B, Series C
- Nagoya Small and Medium Business Investment & Consultation (https://capitalatlas.ai/funds/nagoya-small-and-medium-business-investment-consultation) — Series B, Series C
- Dai-ichi Life Insurance — Series C
- Ant Capital Partners (https://capitalatlas.ai/funds/ant-capital-partners) — Series C
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series C
- AG Capital — Series C
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series C
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series C
- Cybird Co., Ltd. — Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Collabo SANGAKUKAN (https://capitalatlas.ai/funds/collabo-sangakukan) — Series C
- Rakuten Capital (https://capitalatlas.ai/funds/rakuten-capital) — Series C